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Abstract Endothelin-1 (ET-1)[1^31] is a novel hypertensive
peptide that mimics many of the vascular effects of the classic 21
amino acid peptide ET-1[1^21]. However, at variance with ET-
1[1^21] that enhances aldosterone secretion from cultured rat
zona glomerulosa (ZG) cells by acting via ETB receptors, ET-
1[1^31] did not elicit such effect. Both ET-1[1^21] and ET-1-
[1^31] raised the proliferation rate of cultured ZG cells, the
maximal effective concentration being 1038 M. This effect was
blocked by the ETA-receptor antagonist BQ-123 and unaffected
by the ETB-receptor antagonist BQ-788. Quantitative auto-
radiography showed that ET-1[1^21] displaced both [125I]PD-
151242 binding to ETA receptors and [125I]BQ-3020 binding to
ETB receptors in both rat ZG and adrenal medulla, while ET-
1[1^31] displaced only [125I]BQ-3020 binding. The tyrosine
kinase (TK) inhibitor tyrphostin-23 and the p42/p44 mitogen-
activated protein kinase (MAPK) inhibitor PD-98059 abolished
the proliferogenic effect of ET-1[1^31], while the protein kinase-
C (PKC) inhibitor calphostin-C significantly reduced it. ET-1[1^
31] (1038 M) stimulated TK and MAPK activity of dispersed ZG
cells, an effect that was blocked by BQ-123. The stimulatory
action of ET-1[1^31] on TK activity was annulled by tyrphostin-
23, while that on MAPK activity was reduced by calphostin-C
and abolished by either tyrphostin-23 and PD-98059. These data
suggest that ET-1[1^31] is a selective agonist of the ETA-
receptor subtype, and enhances proliferation of cultured rat ZG
cells through the PKC- and TK-dependent activation of p42/p44
MAPK cascade. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Endothelin-1 (ET-1) is the prototype of a family of 21 ami-
no acid peptides acting through two main receptor subtypes,
called ETA and ETB. It is generated from big-ET-1 by cleav-
age at the Trp21-Val/Ile22 bond by the endothelin-converting
enzyme (ECE)-1 [1]. However, evidence has been recently pro-
vided that big-ET-1 may be also selectively cleaved at the
Tyr31-Gly32 bond by a chymase to produce a novel peptide,
named ET-1[1^31] [2].
ET-1[1^31] has been found to reproduce many of the vas-
cular e¡ects of ET-1[1^21], including contraction of porcine
coronary artery and rat aorta [3], raising of intracellular Ca2
concentration in cultured human vascular smooth-muscle cells
(VSMC) [4^6], and stimulation of VSMC proliferation [7].
ETA receptors mediate the vasoconstrictor and VSMC pro-
liferogenic e¡ect of ET-1[1^31] [8]. However, it was contended
that they are involved also in ET-1[1^31] e¡ects [3,4,6].
We have demonstrated that ET-1[1^21] in addition to en-
hancing aldosterone secretion in the rat via the ETB receptor
[9], exerts a marked proliferogenic action on the zona glomer-
ulosa (ZG) of in situ perfused rat adrenal gland. This e¡ect
occurs via ETA receptors coupled with protein kinase (PK) C-
and tyrosine kinase (TK)-dependent signaling pathways [10].
However, the e¡ect of ET-1[1^31] on rat ZG has not been
studied. Thus, the present study was undertaken to investigate
whether ET-1[1^31] a¡ects secretion and proliferation of rat
ZG cells cultured in vitro.
2. Materials and methods
2.1. Cell cultures
Adult male Sprague^Dawley rats (260 þ 30 g body weight) were
purchased from Charles-River (Como, Italy), and the protocol of
the experiment was approved by the local Ethical Committee for
Animal Studies. Rats were decapitated, and their adrenal glands
were promptly removed and cleaned from adherent adipose tissue.
Adrenals were gently decapsulated to separate ZG from the inner
zones, and dispersed ZG cells were obtained by sequential collagenase
digestion and mechanical disaggregation [9]. Dispersed cells were sus-
pended in Eagle’s minimum essential medium (Paisley, UK), supple-
mented with 2% fetal bovine serum (Sigma, St. Louis, MO, USA), 100
U/ml penicillin and 100 Wg/ml streptomycin, and plated in 35-mm
tissue culture dishes at a density of 5U104 cells/dish. They were cul-
tured at 37‡C in a humidi¢ed atmosphere of 95% air^5% CO2, and
employed after 24 h of culture.
2.2. Cell secretion
Culture medium was replaced with fresh medium, which was then
collected after 120 min to evaluate basal cell secretion. New medium
was then added which contained the following compounds: (i) ET-
1[1^21] or ET-1[1^31] (Peptide Institute, Osaka, Japan) (from 10311 to
1037 M); and (ii) ET-1[1^21] or ET-1[1^31] (1038 M) alone or with
1037 M BQ-123 and BQ-788 (Neosystem, Strasbourg, France), which
are selective antagonists of the ETA and ETB receptors, respectively
[2]. A further 120-min incubation was then performed (stimulated
secretion). Some samples were incubated with 1039 M ACTH.
Aldosterone was extracted from the incubation media and puri¢ed
by HPLC [11]. Its concentrations were measured by speci¢c RIA, as
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previously detailed [9]. Values were expressed as percent change from
basal secretion, and six culture dishes for each experimental point
were employed.
2.3. Cell proliferation
Cultures were incubated for 24 h as follows: (i) ET-1[1^21] or ET-
1[1^31] (from 10311 to 1037 M); (ii) ET-1[1^31] (1038 M) alone or in
the presence of 1037 M BQ-123, 1037 M BQ-788, 1035/1034 M phos-
phoramidon (Sigma), 1035 M H-89, 1035 M calphostin-C, 1035 M
tyrphostin-23 and 1034 M PD-98059 (Biomol, Milan, Italy). During
the last 12 h of incubation, 5-bromo-2P-deoxyuridine (BrdU) (Sigma)
was added to the culture medium to a ¢nal concentration of 20
mg/ml.
Cultures were ¢xed in 4% paraformaldehyde for 30 min, and BrdU-
positive (S-phase) cells were detected by immunocytochemistry, using
the Cell Proliferation kit1 of the Amersham Pharmacia (Aylesbury,
UK). The percentage of positive cells was evaluated by counting 5000
cells per dish, and ¢ve dishes for each experimental point were em-
ployed.
2.4. TK and mitogen-activated protein kinase (MAPK) activity
Dispersed ZG cells were put in Medium 199 (Difco, Detroit, MI,
USA) and Krebs^Ringer bicarbonate bu¡er with 0.2% glucose, con-
taining 5 mg/ml of bovine serum albumin (BSA) (Sigma). They were
incubated with ET-1[1^31] (1038 M) alone or in the presence of 1037
M BQ-123 and BQ-788. Other ZG cell preparations were preincu-
bated for 30 min with 1035 M H-89, 1035 M calphostin-C, 1035 M
tyrphostin-23 or 1034 M PD-98059, and then exposed to ET-1[1^31]
(1038 M). The incubation was carried out in a shaking bath at 37‡C
for 15 min, and was stopped by two quick washes with ice-cold PBS.
Dispersed cells were lysed as previously described [12], and then
were Dounce homogenized (20 strokes; Kontes, Vineland, NJ,
USA) on ice for 1 min. Homogenates were centrifuged at 4‡C at
800Ug for 10 min, and then at 12 000Ug for 15 min. Supernatants
were removed, the protein concentration was determined by the
Lowry method using BSA as a standard, and then stored at 380‡C.
TK activity was assayed, using poly (Glu4,Tyr1) (Sigma) as substrate
[13]. MAPK activity was measured by immune complex kinase assay
[14], using anti-MAPK p42/p44 polyclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) and myelinic basic protein (Sig-
ma) as substrate. The procedures have been described previously in
detail [12]. Each experimental point was the mean of four separate
experiments.
2.5. Quantitative autoradiography
Adrenal glands of three rats were immediately frozen at 330‡C by
immersion in isopentane, and stored at 380‡C. Frozen sections (10^
15 Wm thick) were cut in a cryostat (Leitz 1720 Digital) at 320‡C, and
processed for autoradiography as previously detailed [9]. They were
labeled in vitro by incubation for 120 min at 37‡C with 1039 M
[125I]PD-151242 or [125I]BQ-3020 (Amersham), which are selective li-
gands of the ETA and ETB receptors, respectively [2]. The selectivity
of binding was checked by addition of 1037 M BQ-123 or BQ-788.
The ability of ET-1[1^21] and ET-1[1^31] to displace binding was
measured by adding each of them to a concentration ranging from
10311^1037 M. The reaction was stopped by washing the samples
three times in 50 mM Tris^HCl bu¡er. After rinsing, the sections
were rapidly dried, ¢xed in paraformaldehyde vapors at 80‡C for
120 min, and coated with NTB2 nuclear emulsion (Eastman Kodak,
Rochester, NJ, USA). Autoradiographs were exposed for 2 weeks at
4‡C, and then developed with undiluted Kodak D19 developer. They
were stained with hematoxylin-eosin, and observed and photographed
with a Leitz Laborlux microscope.
For each adrenal gland, three unstained autoradiograms were ana-
lyzed by computer-assisted densitometry with a camera-connected
microscope and an IBM-compatible computer equipped with a soft-
ware speci¢cally written for this purpose (Studio Casti Imaging, Ven-
ice, Italy). In each autoradiogram, 10 areas of the ZG (about 36 000
pixels) were analyzed. The density value of the capsule was taken as
the background value.
2.6. Statistics
Data were expressed as means þ S.E.M., and their statistical com-
parison was done by ANOVA, followed by Duncan’s multiple range
test.
3. Results and discussion
Under basal conditions ZG cell cultures produced sizeable
amounts of aldosterone (20^25 pmol/well) ; they responded to
1039 M ACTH stimulation (approximately 5-fold rise) (data
not shown), thereby indicating that ZG cells maintain their
native phenotype after the 24-h in vitro culture conditions of
this study. ET-1[1^21] concentration-dependently increased al-
dosterone secretion, maximal e¡ective concentration being
1038 M (2-fold rise), while ET-1[1^31] was ine¡ective (Fig.
1). The stimulatory e¡ect of 1038 M ET-1[1^21] was abolished
by the ETB-receptor antagonist BQ-788 (1037 M) and unaf-
fected by the ETA-receptor antagonist BQ-123 (Fig. 1), thus
con¢rming that the aldosterone secretagogue action of ET-
1[1^21] is exclusively mediated by the ETB-receptor subtype
[2].
Both ET-1[1^21] and ET-1 [1^31] concentration-depen-
dently increased the percentage of BrdU-positive cells in ZG
cell cultures; the maximal e¡ective concentration eliciting an
about 4.5-fold rise was 1038 M (Fig. 2). The ECE-1 inhibitor
phosphoramidon [15] did not blunt the proliferogenic action
of ET-1[1^31] (Fig. 2), thereby ruling out the possibility that
the e¡ect of this peptide is due to its cleavage to ET-1[1^21],
as reported to occur in cultured bronchial smooth muscle cells
[16]. The proliferogenic e¡ect of 1038 M ET-1[1^31] was
blocked by BQ-123 (1037 M), and una¡ected by BQ-788
(Fig. 2). This ¢nding indicates that the ZG proliferogenic
Fig. 1. E¡ects of ET-1[1^21] and ET-1[1^31] on aldosterone secre-
tion from cultured rat ZG cells (upper panel), and of the ET-recep-
tor antagonists (1037 M) on aldosterone response to 1038 M ET-
1[1^21] or ET-1[1^31] (lower panel). Data, expressed as percent
change from baseline, are means þ S.E.M. (n = 6). *P6 0.01 versus
the baseline value (B); AP6 0.01 versus the respective control value.
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e¡ect of ET-1[1^31], like that of ET-1[1^21] [10], is mediated
by the ETA-receptor subtype. Although the ZG proliferogenic
actions of the two ET-1 peptides display similar e⁄cacy, ET-
1[1^31] was signi¢cantly more potent than ET-1[1^21] (EC50 :
1.1 þ 0.3U10310 M versus 8.2 þ 1.6U10310 M; P6 0.05,
n = 5), an observation consistent with the possibility that
ET-1[1^31], at variance with ET-1[1^21], exclusively binds
the ETA-receptor subtype.
This last contention is supported by autoradiographic stud-
ies. As expected [9], ETA receptors ([125I]PD-151242 BQ-123-
displaceable binding sites) and ETB receptors ([125I]BQ-3020
BQ-788-displaceable binding sites) were mainly present in
both ZG and adrenal medulla (Fig. 3). The quantitative den-
sitometric analysis of autoradiograms showed that ET-1[1^21]
concentration-dependently displaced either [125I]PD-151242 or
[125I]BQ-3020 binding, while ET-1[1^31] displaced only
[125I]PD-151242 binding in both ZG and adrenal medulla
(Fig. 4). Again, ET-1[1^31] was more potent than ET-1-
[1^21] in displacing ETA-receptor binding (EC50 : ZG,
0.6 þ 0.3U10310 M versus 1.1 þ 0.5U1039 M; adrenal medul-
la, 0.5U10310 M versus 0.7U1039 M; P6 0.05, n = 3).
The 1038 M ET-1[1^31]-induced rise in the number of
BrdU-positive cells was signi¢cantly reduced by calphostin-C
(1035 M) and abolished by either tyrphostin-23 (1035 M) or
PD-98059 (1034 M). In contrast, H-89 was ine¡ective (Fig. 5).
ET-1[1^31] (1038 M) enhanced TK and MAPK activities
(about 2-fold) in dispersed ZG cells, and the e¡ect was an-
nulled by 1037 M BQ-123, but not BQ-788 (Fig. 6). Preincu-
bation with 1035 M tyrphostin-23, but not with H-89, cal-
phostin-C or PD-98059, blocked the ET-1[1^31]-induced
stimulation of TK activity (Fig. 6). The ET-1[1^31]-evoked
rise in MAPK activity was annulled by preincubation with
tyrphostin-23 (1035 M) or PD-98059 (1034 M), signi¢cantly
blunted by calphostin-C (1035 M), and una¡ected by H-89
(Fig. 6).
The TK receptor is involved in the activation of p42/p44
MAPKs, ubiquitous members of a family of serine/threonine
kinases, that play a crucial role in cell proliferation [17,18].
Our results strongly suggest that ET-1[1^31] exerts its growth-
promoting action by activating the TK^MAPK signaling
Fig. 2. E¡ects of ET-1[1^21] and ET-1[1^31] on the proliferation
rate of cultured rat ZG cells (upper panel), and of the ET-receptor
antagonists (1037 M) and phosphoramidon (PPR) (1035 or 1034 M)
on the proliferogenic response to 1038 M ET-1[1^31] (lower panel).
Data are means þ S.E.M. (n = 5). P6 0.05 and *P6 0.01 versus the
respective baseline value (B). AP6 0.01 versus the respective control
value.
Fig. 3. Autoradiograms of unstained frozen sections of rat adrenal
gland incubated with 1039 M [125I]PD-151242 (A) or 1039 M
[125I]BQ-3020 (B). Binding of [125I]PD-121542 to ETA receptors was
eliminated by 1037 M BQ-123 (C) and binding of [125I]BQ-3020 to
ETB receptors was completely displaced by 1037 M BQ-788 (D).
ET-1[1^31] eliminated binding to ETA receptors (E), without a¡ect-
ing binding to ETB receptors (F). c, Gland capsule; AM, adrenal
medulla. 67U.
FEBS 24443 27-12-00
G. Mazzocchi et al./FEBS Letters 487 (2000) 194^198196
pathway. This contention is based on the following pieces of
evidence: (i) the TK inhibitor tyrphostin-23 [19] and the
MEK1 inhibitor PD-98059 [20] block the ET-1[1^31]-induced
rise in the number of BrdU-positive ZG cells ; (ii) these inhib-
itors per se do not evoke any apparent e¡ect on the basal rate
of DNA synthesis, thus excluding the possibility that these
results were due to a non-speci¢c toxic e¡ect on cultured
ZG cells ; (iii) ET-1[1^31] stimulates both TK and MAPK
activity in dispersed rat ZG cells and the e¡ect is blocked
by BQ-123; and (iv) like PD-98059, tyrphostin-23 blocks the
ET-1[1^31]-induced stimulation of MAPK activity.
Evidence indicates that, in addition to TK, G protein-
coupled receptors can activate the MAPK cascade [21],
through both protein kinase-C (PKC)- [22^24] and PKA-de-
pendent pathways [24,25]. Accordingly, angiotensin-II was
found to stimulate mitogenesis and MAPK activity in bovine
ZG cells via a PKC-dependent and a PKC-independent path-
way [26], and cyclic-AMP was shown to activate MAPK and
to enhance proliferation of ZG cells [27]. Our data demon-
strate the involvement of the PKC pathway in the MAPK-
mediated ZG proliferogenic action of ET-1[1^31]. In fact, the
PKC inhibitor calphostin-C [28] partially reverses ZG cell
proliferation and MAPK activation induced by ET-1[1^31].
PKC-dependent and TK-dependent MAPK activation in rat
ZG cells are conceivably two independent pathways, because
calphostin-C does not a¡ect ET-1[1^31]-induced stimulation
of TK activity. In contrast, adenylate cyclase/PKA pathway
Fig. 4. Evaluation by quantitative densitometry of the displacement
of [125I]PD-151242 and [125I]BQ-3020 (total binding, TB) by ET-1-
[1^21] and ET-1[1^31] in the ZG (upper panels) and adrenal medul-
la (lower panels). Data are means þ S.E.M. (n = 3). P6 0.05 and
*P6 0.01 versus the respective TB value; aP6 0.05 and AP6 0.01
versus the respective background value.
Fig. 5. E¡ects of H-89 (1035 M), calphostin-C (1035 M), tyrphos-
tin-23 (1035 M) and PD-98059 (1034 M) on 1038 M ET-1[1^31]-in-
duced stimulation of the proliferation rate of cultured rat ZG cells.
Data are means þ S.E.M. (n = 5). P6 0.05 and *P6 0.01 versus the
respective baseline value (B); AP6 0.01 versus the respective control
value.
Fig. 6. E¡ects of the ET-receptor antagonists (1037 M) (upper pan-
els), and of the preincubation with H-89 (1035 M), calphostin-C
(1035 M), tyrphostin-23 (1035 M) or PD-98059 (1034 M) (middle
and lower panels) on 1038 M ET-1[1^31]-induced stimulation of TK
and MAPK activity of dispersed rat ZG cells. Data are means
þ S.E.M. (n = 4). P6 0.05 and *P6 0.01 versus the respective base-
line value (B); aP6 0.05 and AP6 0.01 versus the respective control
value.
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does not appear to play a relevant role, inasmuch as the PKA
inhibitor H-89 [29] a¡ects neither ZG cell proliferogenic nor
the TK- and MAPK-activating action of ET-1[1^31]. This
¢nding agrees with the recent report of the inability of
ACTH to stimulate MAPK in rat ZG cells [30].
In summary, the present results collectively indicate that
ET-1[1^31] (i) is a selective agonist of the ETA receptor,
and (ii) enhances proliferation of cultured rat ZG cells
through both a primary TK-dependent and a secondary
PKC-dependent activation of the p42/p44 MAPK cascade.
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